Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2013 1
2021 1
2023 1
2024 1
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
A multinational cross-sectional study on the prevalence and predictors of long COVID across 33 countries.
Zaazouee MS, Nada EA, Al-Kafarna M, Shaheen A, Ramu SK, Hafez AH, Matar SG, Assar A, Elshennawy M, Abu El-Enien H, Redwan HJ, Elsayed SM, Omran MJ, Salloum OH, Almadhoon H, Mamdouh M, Wahsh EA, Nourelden AZ, Elshanbary AA, Abdel-Aziz W, Rashid HH, Basheti I, Ragab KM, Masoud AT, Abushouk AI; Long-COVID International Team (LCIT). Zaazouee MS, et al. Sci Rep. 2025 Aug 3;15(1):28299. doi: 10.1038/s41598-025-10120-z. Sci Rep. 2025. PMID: 40754541 Free PMC article.
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.
Demidov L, Samoylenko I, Kharkevich G, Orlova K, Moiseenko V, Utyashev I, Stroyakovskiy D, Kozlov V, Zimina A, Mochalova A, Demidova S, Lyadova M, Kutkovich A, Skopin P, Kovalenko N, Safina S, Volkov V, Semiletova Y, Vaschenko V, Kislov N, Poltoratskiy A, Shumskaya I, Kolomiets S, Sobolev A, Belogortsev I, Odintsova S, Rastogi S, Andabekov T, Penkov K, Semenova A, Obukhov A, Belyakovsky V, Yurchenkov A, Gladkov O, Neve R, Falaleeva N, Poddubskaya E, Vaibhav A, Kirtbaya D, Chapko Y, Smagina M, Fadeeva N, Sorokina I, Mikhailova E, Linkova Y, Zinkina-Orikhan A, Lutskii A, Gabidullin R, Rzaev R, Kryukov F. Demidov L, et al. Among authors: vaibhav a. Eur J Cancer. 2025 Sep 9;227:115674. doi: 10.1016/j.ejca.2025.115674. Epub 2025 Aug 5. Eur J Cancer. 2025. PMID: 40795521 Clinical Trial.
Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].
Demidov L, Samoylenko I, Kharkevich G, Orlova K, Moiseenko V, Utyashev I, Stroyakovskiy D, Kozlov V, Zimina A, Mochalova A, Demidova S, Lyadova M, Kutkovich A, Skopin P, Kovalenko N, Safina S, Volkov V, Semiletova Y, Vaschenko V, Kislov N, Poltoratskiy A, Shumskaya I, Kolomiets S, Sobolev A, Belogortsev I, Odintsova S, Rastogi S, Andabekov T, Penkov K, Semenova A, Obukhov A, Belyakovsky V, Yurchenkov A, Gladkov O, Neve R, Falaleeva N, Poddubskaya E, Vaibhav A, Kirtbaya D, Chapko Y, Smagina M, Fadeeva N, Sorokina I, Mikhailova E, Linkova Y, Zinkina-Orikhan A, Lutskii A, Gabidullin R, Rzaev R, Kryukov F. Demidov L, et al. Among authors: vaibhav a. Eur J Cancer. 2025 Oct 1;228:115732. doi: 10.1016/j.ejca.2025.115732. Epub 2025 Aug 30. Eur J Cancer. 2025. PMID: 40886565 No abstract available.